Evolus, Inc.

NASDAQ:EOLS

Drug Manufacturers - Specialty & Generic

Healthcare
$7.07 -2.00%

-$0.14 today

Market cap
$467.95M
Beta
1.33
P/E (TTM)
-9.9
EPS (TTM)
-$0.67
52W Low $3.86High $10.20

Volume 0.80M

Average 0.86M

EOLS Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Evolus, Inc.NASDAQ: EOLS

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $51.98M fell 8.2% year over year, behind the +3.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 4.9% from the prior quarter. Over 3 fiscal years it compounded at +15.9% a year.

Context

  • Selling, general & admin amounted to 74.3% of revenue in FY2025, unchanged from a year earlier.
  • Selling, general & admin increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 4 analysts of $292.95M (+32.7%) for the fiscal year ending Dec 2026, a step up from the +11.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$51.98M-4.9% QoQ
Last fiscal yearDec 2025
$220.79M+11.5% YoY
LTMMar 2026
$216.13M+3.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.2%+26.1%+34.3 pp
1 year+11.5%+32.7%+21.2 pp
3-year CAGR+15.9%+22.2%+6.3 pp
5-year CAGR+19.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
220.79M USD
Year-over-year change
+11.5%
4-year CAGR
+18.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How EOLS compares with its peers on the latest reported figures

No competitor Selling, General & Admin figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue99.67M148.62M202.09M266.27M297.18M
Cost of Revenue43.53M58.84M61.56M83.97M104.41M
Gross Profit56.14M89.77M140.53M182.3M192.76M
Gross Margin56.3%60.4%69.5%68.5%64.9%
Research & Development2.06M6.74M15.43M9.17M9.58M
Selling, General & Admin112.07M141.84M164.94M198.03M220.79M
Operating Expenses100.54M155.1M189.76M216.72M230.36M
Depreciation & Amortization6.31M3.72M5.87M6.02M8.74M
EBITDA(39.06M)(53.85M)(41.81M)(25M)(22.53M)
EBITDA Margin-39.2%-36.2%-20.7%-9.4%-7.6%
Operating Income(44.41M)(65.33M)(49.23M)(34.41M)(37.6M)
Operating Margin-44.6%-44.0%-24.4%-12.9%-12.7%
Interest Income1K119K860K3.26M1.93M
Interest Expense1.4M9.1M13.83M18.74M19.69M
Other Income / Expenses(2.36M)(8.99M)(12.28M)(15.35M)(13.36M)
Income Before Tax(46.77M)(74.32M)(61.51M)(49.76M)(50.96M)
Pre-Tax Margin-46.9%-50.0%-30.4%-18.7%-17.1%
Income Tax Expense42K95K176K664K677K
Net Income(46.81M)(74.41M)(61.69M)(50.42M)(51.64M)
Net Margin-47.0%-50.1%-30.5%-18.9%-17.4%
EPS (Basic)(0.94)(1.33)(1.08)(0.81)(0.80)
EPS (Diluted)(0.94)(1.33)(1.08)(0.81)(0.80)
Weighted Avg Shares49.77M56.07M56.92M62.02M64.47M
Weighted Avg Shares (Diluted)49.77M56.07M56.92M62.02M64.47M

Evolus, Inc.

NASDAQ:EOLS

Intrinsic Alpha fair value

Locked

Current Price

$7.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.